NEW CAMKII THERAPEUTIC TARGETS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION

Abstract

Deaths associated with impaired heart muscle relaxation and unstable cardiac cycle rhythm are increasing. The mechanisms by which these pathologies occur are not understood and clinical therapies are lacking. We have novel evidence to suggest that a key signalling protein, CaMKII, is critically involved in the development of these forms of heart pathology. This goal of this project is to identify how CaMKII is implicated in heart failure and dysrhythmia as a basis for designing new therapies.

Related publications (1)

Cardiomyocyte functional screening: interrogating comparative electrophysiology of high-throughput model cell systems

Simon P Wells, Helen M Waddell, Choon Boon Sim, Shiang Y Lim, Gabriel B Bernasochi, Davor Pavlovic, Paulus Kirchhof, Enzo R Porrello, Lea MD Delbridge, James R Bell

2019-12-01

Cardiac arrhythmias of both atrial and ventricular origin are an important feature of cardiovascular disease. Novel antiarrhythmic..